Eva Zupančič , JoanaM Silva , Mafalda A. Videira , João N. Moreira , Helena F. Florindo
{"title":"一种新型纳米颗粒乳腺癌免疫治疗疫苗的研制","authors":"Eva Zupančič , JoanaM Silva , Mafalda A. Videira , João N. Moreira , Helena F. Florindo","doi":"10.1016/j.provac.2014.07.011","DOIUrl":null,"url":null,"abstract":"<div><p>Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly- lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs presented a narrow size distribution with an average size of 167<!--> <!-->nm witha polidisperity index (PdI)0.167 and zeta potential values close to neutrality (-1.66<!--> <!-->mV), which is desired for a particulate cancer vaccine to overcome their premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 57.5% and 29<!--> <!-->μg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z- Average (180<!--> <!-->nm with a PdI 0.18), and ZP (ZP -1.78<!--> <!-->mV), but lower EE and LC (32% and 16<!--> <!-->μg/mg). The effect of NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.</p></div>","PeriodicalId":89221,"journal":{"name":"Procedia in vaccinology","volume":"8 ","pages":"Pages 62-67"},"PeriodicalIF":0.0000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.011","citationCount":"3","resultStr":"{\"title\":\"Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy\",\"authors\":\"Eva Zupančič , JoanaM Silva , Mafalda A. Videira , João N. Moreira , Helena F. Florindo\",\"doi\":\"10.1016/j.provac.2014.07.011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly- lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs presented a narrow size distribution with an average size of 167<!--> <!-->nm witha polidisperity index (PdI)0.167 and zeta potential values close to neutrality (-1.66<!--> <!-->mV), which is desired for a particulate cancer vaccine to overcome their premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 57.5% and 29<!--> <!-->μg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z- Average (180<!--> <!-->nm with a PdI 0.18), and ZP (ZP -1.78<!--> <!-->mV), but lower EE and LC (32% and 16<!--> <!-->μg/mg). The effect of NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.</p></div>\",\"PeriodicalId\":89221,\"journal\":{\"name\":\"Procedia in vaccinology\",\"volume\":\"8 \",\"pages\":\"Pages 62-67\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.provac.2014.07.011\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Procedia in vaccinology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1877282X14000125\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Procedia in vaccinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1877282X14000125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Development of a Novel Nanoparticle-based Therapeutic Vaccine for Breast Cancer Immunotherapy
Nanoparticles (NPs) have great potential as advanced delivery systems for cancer immunotherapy. PEGylated-Poly- lactide-co-glycolic acid-based (PLGA-PEG) NPs were prepared by double-emulsion solvent evaporation technique, using ovalbumin (OVA) as a model antigen. Glycol Chitosan and block co-polymer Pluronic F127 were used in order to best attain the most efficient parameters for cancer immunotherapy. OVA-loaded PLGA-PEG NPs presented a narrow size distribution with an average size of 167 nm witha polidisperity index (PdI)0.167 and zeta potential values close to neutrality (-1.66 mV), which is desired for a particulate cancer vaccine to overcome their premature capture by macrophages. The encapsulation efficiency (EE) and loading capacity (LC) of these NPs were 57.5% and 29 μg/mg, respectively. PLGA-PEG NPs modified with Pluronic F127 presented slightly higher Z- Average (180 nm with a PdI 0.18), and ZP (ZP -1.78 mV), but lower EE and LC (32% and 16 μg/mg). The effect of NPs on dendritic cell viabilitywas evaluated using Alamar Blue® assays.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
